Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Immune Pharmaceuticals (IMNP) Share Price

Media stories about Immune Pharmaceuticals (NASDAQ:IMNP) have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Immune Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.3869652694135 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of Immune Pharmaceuticals traded down $0.01, hitting $0.21, during trading hours on Tuesday, MarketBeat reports. 825,654 shares of the company were exchanged, compared to its average volume of 1,104,721. Immune Pharmaceuticals has a 1 year low of $0.21 and a 1 year high of $3.43. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.31 and a current ratio of 0.31.

Immune Pharmaceuticals (NASDAQ:IMNP) last released its quarterly earnings results on Tuesday, May 15th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.05.

Several research firms have recently commented on IMNP. Maxim Group set a $2.00 price target on Immune Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, April 3rd. ValuEngine upgraded Immune Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.

Immune Pharmaceuticals Company Profile

Immune Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops therapeutic agents in the fields of immuno-inflammation, dermatology, and immuno-oncology. The company's lead product candidate is bertilimumab, a clinical-stage human antibody, which is in Phase II clinical trial that targets eotaxin-1 for the treatment of bullous pemphigoid, crohn's, and ulcerative colitis diseases.

Insider Buying and Selling by Quarter for Immune Pharmaceuticals (NASDAQ:IMNP)

Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply